Feeling run-down or catching every cold that comes your way? It might be time to check your vitamin intake. A strong immune ...

Some people may be more vulnerable to infections and illnesses than others and several factors can be to blame Here’s what a ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

One of winter’s most overlooked immune saboteurs is the dramatic drop in natural vitamin D production. During warmer months, ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today ...

Broad rim lesions, which have wider rims of immune cells, are associated with faster disease progression in MS, per a study.

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

Discover why adults over 65 require additional vitamin D, from declining skin production to medication interactions, and ...

FDA meeting requested following Phase IIb trial showing median overall survival of 17.6 months without chemotherapy Immutep ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS 1; Mature overall survival ...